Get started
Author

Ovidio Fernández Calvo

Observed names: Fern?ndez Calvo, Ovidio, Fernández Calvo, Ovidio, O. Fernandez-Calvo, O. Fernández-Calvo, Ovidio Fernandez Calvo, Ovidio Fernandez-Calvo, Ovidio Fernandez‐Calvo, Ovidio Fernández, Ovidio Fernández-Calvo
ORCID: 0000-0001-5283-9754
Observed ORCID: 0000-0001-5283-9754
OpenAlex ID: A5113916334
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
2017 · V. Conteduca, D. Wetterskog, et al. · Annals of Oncology · 275
Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study
2021 · J. Ruiz-Bañobre, A. Molina-Díaz, et al. · ESMO Open · 47
PDF
Molecular basis of hypertension side effects induced by sunitinib
2010 · Guadalupe Aparicio-Gallego, Francisco J. Afonso-Afonso, et al. · Anti-Cancer Drugs · 42
Weekly cabazitaxel plus prednisone is effective and less toxic for ‘unfit’ metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial
2017 · Miguel Ángel Climent, Begoña Pérez-Valderrama, et al. · European Journal of Cancer · 21
Renal cell carcinoma: complete pathological response in a patient with gastric metastasis of renal cell carcinoma
2010 · Rosario García-Campelo, Maria Quindós, et al. · Anti-Cancer Drugs · 20
SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021)
2022 · Begoña P. Valderrama, Aránzazu González-del-Alba, et al. · Clinical & Translational Oncology · 19
A correlative biomarker study and integrative prognostic model in chemotherapy‐naïve metastatic castration‐resistant prostate cancer treated with enzalutamide
2022 · María P. Fernandez‐Perez, Enrique Perez‐Navarro, et al. · The Prostate · 17
PDF
Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor
2013 · F. J. Afonso, U. Anido, et al. · Clinical & Translational Oncology · 14
The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)
2019 · Albert Font, Raquel Luque, et al. · Targeted Oncology · 13
Radium-223 dichloride: a new paradigm in the treatment of prostate cancer
2015 · Urbano Anido Herranz, Ovidio Fernández Calvo, et al. · Expert Review of Anticancer Therapy · 13
Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer
2024 · Urbano Anido-Herranz, Ovidio Fernandez-Calvo, et al. · Frontiers in Oncology · 10
Prostate cancer perspectives after chaarted: Optimizing treatment sequence
2016 · Sergio Vázquez Estévez, Urbano Anido Herranz, et al. · Critical Reviews in Oncology/Hematology · 8
Renal cell carcinoma: complete response
2010 · Ovidio Fernández Calvo, Diana Dopico Vázquez, et al. · Anti-Cancer Drugs · 8
Efficacy and safety of atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer: An interim analysis of the ATEZOBLADDERPRESERVE phase II trial (SOGUG-2017-A-IEC(VEJ)-4).
2022 · Sergio Vazquez-Estevez, Ovidio Fernandez-Calvo, et al. · Journal of Clinical Oncology · 7
Follow-up of primary melanoma patients with high risk of recurrence: recommendations based on evidence and consensus
2022 · Begoña Campos-Balea, Ovidio Fernández-Calvo, et al. · Clinical & Translational Oncology · 7
Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU)
2016 · Jorge García, Lucia Santomé, et al. · Current Oncology Reports · 7
Enzalutamide: A new prostate cancer targeted therapy against the androgen receptor
2015 · Martín Lázaro Quintela, Luis León Mateos, et al. · Cancer Treatment Reviews · 7
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
2018 · U. Anido-Herranz, N. Fernández-Núñez, et al. · Clinical & Translational Oncology · 5
PDF
Neuroendocrine Pulmonary Tumors of Low, Intermediate and High Grade: Anatomopathological Diagnosis—Prognostic and Predictive Factors
2018 · José Manuel Cameselle-Teijeiro, José Antonio Mato Mato, et al. · Molecular Diagnosis & Therapy · 5
Vinflunine (VFL) as second-line chemotherapy for patients with transitional cell carcinoma of the urothelium (TCCU): A multicenter retrospective study.
2013 · Guillermo De Velasco, Isabel Chirivella, et al. · Journal of Clinical Oncology · 4
Real-world data on avelumab in first-line maintenance therapy for advanced or metastatic urothelial carcinoma: the SOGUG-AVELUMAB RWD study
2025 · Ovidio Fernández, Aurea Molina, et al. · Clinical & Translational Oncology · 3
PDF
Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer
2024 · Enrique Perez-Navarro, Vincenza Conteduca, et al. · Cancers · 3
Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib
2022 · Guillermo de Velasco, Teresa Alonso-Gordoa, et al. · Clinical Genitourinary Cancer · 3
A phase II multicenter biomarker trial to study the predictive value of TMPRSS2-ERG before enzalutamide treatment in chemo-naïve metastatic castration-resistant prostate cancer.
2019 · Enrique Grande, Maria Piedad Fernandez Perez, et al. · Journal of Clinical Oncology · 3
Weekly cabazitaxel in "unfit" metastatic castration-resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment: Preliminary results of CABASEM-SOGUG phase II trial.
2015 · Ovidio Fernandez Calvo, Eva Fernandez Parra, et al. · Journal of Clinical Oncology · 3
Works count: 77
Citation count: 591
H-index: 10
I10-index: 11
Year
Topic
Type